



LUNG-MAP

A lung cancer precision medicine trial


Major Expansion is Here, New Protocol Activated

The **Lung-MAP** master protocol has changed to include more lung cancer patients, to adapt to changes in the therapeutic landscape, and to better reflect the study structure.

The **S1400** screening protocol is closed to accrual, and the new **LUNGMAP** screening protocol is activated. **LUNGMAP** changes include:

- **Eligibility for patients** with all types of non-small cell lung cancer
- **Collection of whole blood** on a subset of patients for a ctDNA assay
- **One consent form** that combines screening and pre-screening
- **A mandate** requiring sites to use the National Cancer Institute's CIRB for sites that open **LUNGMAP** and its sub-studies
- **A new study** structure in which sub-studies stand alone
- **New "version control"** protocols that group sub-studies by series, including biomarker-driven sub-studies called S1900X and non-match sub-studies called S1800X

Current Schema:



LEARN MORE AT
WWW.LUNG-MAP.ORG



What will happen to my patients?

Patients Registered on S1400 Pre-Screening & Screening:

- Patients registered to S1400 will remain in S1400 and will not need to be re-registered to the new LUNGMAP screening protocol
- Patients in pre-screening prior to progression will continue to be followed in S1400 per protocol. Upon submission of the S1400 Notice of Progression, the patients will be assigned to a sub-study
- The S1400 Request for Sub-study Reassignment can continue to be submitted for patients who are not eligible for their most recently assigned sub-study
- The S1400 Request for New Sub-study Assignment can continue to be submitted for patients who progress on or after a sub-study
- Any open sub-study (in the S1400, S1800, and S1900 series) will be an option for patients who progress on pre-screening, patients who need a sub-study reassignment, and patients who need a new sub-study assignment, dependent on their biomarker profiling results

Patients Registered on LUNGMAP Pre-Screening & Screening:

- Sub-study assignment process on LUNGMAP is identical to S1400 in terms of screening vs. pre-screening, turnaround times, and form submission
- Patients with squamous cell carcinoma who are registered under the LUNGMAP screening protocol will be able to be assigned to any open sub-study, including the legacy S1400 sub-studies open to accrual (currently S1400F), dependent on their biomarker profiling results
- Patients with mixed squamous or non-squamous histology NSCLC who are registered under the LUNGMAP screening protocol will be able to be assigned to any open sub-study in the new S1800 and S1900 series, dependent on their biomarker profiling results



Dr. Vali Papadimitrakopoulou

Lung-MAP Principal Investigator
Chief of Thoracic Medical Oncology
and Professor of Medicine
University of Texas
MD Anderson Cancer Center

“We have more than 200,000 new cases of non-small cell lung cancer in the United States each year, and we desperately need new treatments. When most people are diagnosed with non-small cell lung cancer, their cancer has already grown and spread to other organs. If standard therapies don’t work for these patients — and often they don’t — they need alternatives. Lung-MAP provides those alternatives.”

STUDY CONTACTS GOT A LUNG-MAP QUESTION? HERE’S WHO TO CALL

General medical questions:
LUNGMAP@swog.org

Eligibility + Imaging + Data Submission
SWOG Data Operations, (206) 652-2267
LUNGMAPQuestion@crab.org

Protocol + Regulatory:
SWOG Operations Office,
(210) 614-8808 ext 1003
mnorman@swog.org

Treatment + Toxicity Study Distribution Lists:

S1400A: S1400AMedicalQuery@swog.org S1400G: S1400GMedicalQuery@swog.org
S1400I: S1400IMedicalQuery@swog.org S1400K: S1400KMedicalQuery@swog.org
S1900A: S1900AMedicalQuery@swog.org S1800A: S1800AMedicalQuery@swog.org
S1400F: S1400FMedicalQuery@swog.org

Funding Questions: SWOG Group Chair’s Office, funding@swog.org

For additional information, see funding memos.